Braveheart Bio, Inc.

Braveheart Bio, Inc. が 2026年9月8日 に発表した内容

企業自身の 8-K から。

経営陣の発言

“Our clinical programs continue to advance, and our IPO this summer has provided a strong financial foundation to advance the development of our global Phase 3 programs and evaluate the potential of BHB-1893 as the preferred treatment option in two indications,”

発表資料から逐語で引用し、書類が氏名のある人物に帰属させている場合にのみ表示します。

株価の反応

発表は引け後か寄り前に出るため、ここでの値動きは次の取引日のものです。

Braveheart Bio, Inc. の事業内容

Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Braveheart Bio’s lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Braveheart Bio is aiming to address the limitations of currently available CMIs by designing BHB-1893 for rapid onset, consistent depth of response, preservation of systolic function, prompt reversibility, and a straightforward approach to titration and monitoring.

発表資料の末尾に記載された、企業自身による説明です。